ARTICLE: Colloidal Oatmeal Part II: Atopic Dermatitis in Special Populations and Clinical Efficacy and Tolerance Beyond Eczema.
Antineoplastic Agents
/ adverse effects
Avena
/ chemistry
Colloids
Dermatitis, Atopic
/ ethnology
Dermatologic Agents
/ administration & dosage
Drug Eruptions
/ drug therapy
Hand Dermatoses
/ drug therapy
Humans
Plant Extracts
/ administration & dosage
Psoriasis
/ drug therapy
Skin
/ drug effects
Skin Cream
/ administration & dosage
Skin Pigmentation
Treatment Outcome
Journal
Journal of drugs in dermatology : JDD
ISSN: 1545-9616
Titre abrégé: J Drugs Dermatol
Pays: United States
ID NLM: 101160020
Informations de publication
Date de publication:
01 Oct 2020
01 Oct 2020
Historique:
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
8
6
2021
Statut:
ppublish
Résumé
Colloidal oatmeal has a diverse array of applications, clinical benefits, and uses beyond atopic dermatitis. First and foremost, it has been shown to be of benefit in the treatment of atopic dermatitis in skin of color. It has also been shown to be of benefit in the treatment of hand dermatitis, xerosis, psoriasis, skin manifestations of diabetes, and in the treatment of cutaneous adverse effects associated with oncologic therapies. In Part II of this 2-part series, we examine the efficacy, safety, and expansive clinical applications of colloidal oatmeal. J Drugs Dermatol. 2020;19:10(Suppl):s8-11.
Substances chimiques
Antineoplastic Agents
0
Colloids
0
Dermatologic Agents
0
Plant Extracts
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM